Hospira Likely Will Revisit 2004 Guidance At End Of Summer Season
This article was originally published in The Gray Sheet
Executive Summary
Hospira is maintaining its "conservative" top-line guidance for the 2004 second half - at least in the eyes of some Wall Street onlookers - due to an expected slowdown in hospital product sales this summer